- Home
- IONS vs INGM Comparison
IONS vs INGM Comparison
Compare IONS & INGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- INGM
- Stock Information
- Founded
- IONS 1989
- INGM 1979
- Country
- IONS United States
- INGM United States
- Employees
- IONS N/A
- INGM N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- INGM
- Sector
- IONS Health Care
- INGM
- Exchange
- IONS Nasdaq
- INGM NYSE
- Market Cap
- IONS 6.0B
- INGM 5.7B
- IPO Year
- IONS 1991
- INGM 2024
- Fundamental
- Price
- IONS $34.34
- INGM $22.73
- Analyst Decision
- IONS Buy
- INGM
- Analyst Count
- IONS 18
- INGM 0
- Target Price
- IONS $62.00
- INGM N/A
- AVG Volume (30 Days)
- IONS 1.1M
- INGM 775.8K
- Earning Date
- IONS 11-06-2024
- INGM 11-12-2024
- Dividend Yield
- IONS N/A
- INGM N/A
- EPS Growth
- IONS N/A
- INGM 0.17
- EPS
- IONS N/A
- INGM 1.43
- Revenue
- IONS $803,067,000.00
- INGM $47,658,502,000.00
- Revenue This Year
- IONS N/A
- INGM N/A
- Revenue Next Year
- IONS $16.31
- INGM N/A
- P/E Ratio
- IONS N/A
- INGM $15.93
- Revenue Growth
- IONS 30.57
- INGM N/A
- 52 Week Low
- IONS $34.24
- INGM $22.25
- 52 Week High
- IONS $54.44
- INGM $25.69
- Technical
- Relative Strength Index (RSI)
- IONS 26.91
- INGM N/A
- Support Level
- IONS $37.18
- INGM N/A
- Resistance Level
- IONS $40.07
- INGM N/A
- Average True Range (ATR)
- IONS 1.38
- INGM 0.00
- MACD
- IONS -0.26
- INGM 0.00
- Stochastic Oscillator
- IONS 1.58
- INGM 0.00
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About INGM INGRAM MICRO HOLDING CORPORATION
Ingram Micro Holding Corp is a technology company for the global information technology ecosystem. It plays a vital role in the IT sales channel, bringing products and services from technology manufacturers and cloud providers to business-to-business technology experts. The company also provide a broad range of technology services, including financing, specialized marketing, and lifecycle management, as well as technical pre- and post-sales professional support.